Global Alzheimer’s Therapeutics Market Overview
According to SPER Market Research, the Global Alzheimer’s Therapeutics Market is estimated to reach USD XX billion by 2033 with a CAGR XX%.
Alzheimer's disease is a degenerative neurological disorder that typically affects elderly people, causing a decline in cognitive ability and interfering with daily life. It is the most prevalent type of dementia and is characterised by a gradual loss of memory, reasoning skills, and the ability to do routine tasks. The specific aetiology of Alzheimer's disease is unknown, however it is thought to be a combination of hereditary, environmental, and lifestyle factors. Because there is no one test for Alzheimer's, the diagnosis is based on a medical history, physical examination, and cognitive testing. While there is presently no cure, medications can temporarily alleviate symptoms and reduce the disease's course. Carers play an important role in assisting people with Alzheimer's disease, and ongoing research aims to better understand the disease and develop more effective treatments.
Exploring the Growth Drivers of the Global Alzheimer’s Therapeutics Industry
The rise in Alzheimer's disease prevalence in both developed and emerging nations is driving the growth of the global Alzheimer's treatments market. Furthermore, the increased awareness of the condition around the world, as well as a few other factors such as a rise in the number of diagnosed patients, has heightened the need for therapies for Alzheimer's disease. Furthermore, the availability of medications for the treatment of Alzheimer's disease, such as Aricept, Exelon and Memantine drives market expansion. Because of breakthroughs in therapy and drug development procedures throughout the years, the Alzheimer's therapeutics industry has grown significantly. Furthermore, the increased demand for effective Alzheimer's disease treatment and therapy choices motivates big pharmaceutical companies to engage in R&D, resulting in future growth potential. Furthermore, the presence of strong pipeline medications is one of the elements expected to provide significant growth prospects in the future.
What challenges does the Global Alzheimer’s Therapeutics Market face?
The Alzheimer's therapeutics market faces several challenges that hinder the development and availability of effective treatments. The complexity of Alzheimer's disease itself is a huge challenge. Because the exact source and course of the disease are unknown, it is difficult to target specific therapeutic measures. Furthermore, clinical trials for Alzheimer's medications frequently fail, which can be ascribed to the disease's heterogeneity as well as the problems of patient recruitment and selection. Another challenge is the time-consuming and costly medication development process, which includes stringent testing and regulatory regulations. Furthermore, the lack of accurate biomarkers for early diagnosis, as well as a poor understanding of disease mechanisms, make it difficult to identify feasible pharmacological targets.
In what ways has the COVID-19 pandemic affected Global Alzheimer’s Therapeutics Market?
The COVID-19 outbreak has boosted growth in the global Alzheimer's treatments industry. Patients with Alzheimer's disease were more sensitive to coronavirus infection. As a result, the prolonged lockdown contributed to more severe neuropsychiatric symptoms. As the number of COVID-19 infections in Alzheimer's disease patients increased during the pandemic, so did the demand for Alzheimer's medicines.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Drug Class, By Distribution Channel, By Drug Name
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | AbbVie inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Biogen, Merck & Co. Inc., Cipla Ltd., DAIICHI SANKYO COMPANY LIMITED, Dr. Reddy’s Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lannett Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Novartis AG, Sun Pharmaceuticals Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Viatris Inc., Zydus Lifesciences Ltd., Others |
Key Target Audience:
- Government Agencies and Regulatory Bodies
- Healthcare Professionals
- Patients and Caregivers
- Pharmaceutical Companies
- Research Institutes
Global Alzheimer’s Therapeutics Market Segmentation:
1. By Drug Class:
- Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Drug Class, 2023-2033
- holinesterase inhibitors
- N-Methyl-D-Aspartate (NDMA) receptor antagonist
2. By Distribution Channel:
- Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Distribution Channel, 2023-2033
- Hospital Pharmacy
- Drug Store and Retail Pharmacy
- Online Pharmacy
3. By Drug Name:
- Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Drug Name, 2023-2033
- Donepezil
- Galantamine
- Manufactured Combination of Memantine and Donepezil
- Memantine
- Rivastigmine
4. By Region:
- Asia-Pacific
- Europe
- Middle East & Africa
- North America
- Latin America
Key Topics Covered in the Report:
- Global Alzheimer’s Therapeutics Market Size (FY’2023-FY’2033)
- Overview of Global Alzheimer’s Therapeutics Market
- Segmentation of Global Alzheimer’s Therapeutics Market By Drug Class (Cholinesterase inhibitors, N-Methyl-D-Aspartate receptor antagonist, Others)
- Segmentation of Global Alzheimer’s Therapeutics Market By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy)
- Segmentation of Global Alzheimer’s Therapeutics Market By Drug Name (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil)
- Statistical Snap of Global Alzheimer’s Therapeutics Market
- Growth Analysis of Global Alzheimer’s Therapeutics Market
- Problems and Challenges in Global Alzheimer’s Therapeutics Market
- Competitive Landscape in the Global Alzheimer’s Therapeutics Market
- Impact of COVID-19 and Demonetization on Global Alzheimer’s Therapeutics Market
- Details on Recent Investment in Global Alzheimer’s Therapeutics Market
- Competitive Analysis of Global Alzheimer’s Therapeutics Market
- Key Players in the Global Alzheimer’s Therapeutics Market
- SWOT Analysis of Global Alzheimer’s Therapeutics Market
- Global Alzheimer’s Therapeutics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Alzheimer’s Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Alzheimer’s Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Alzheimer’s Therapeutics Market
7. Global Alzheimer’s Therapeutics Market, By Drug Class (USD Million)
7.1. Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Drug Class, 2023-2033
7.2. Cholinesterase inhibitors
7.3. N-Methyl-D-Aspartate (NDMA) receptor antagonist
7.4. Others
8. Global Alzheimer’s Therapeutics Market, By Distribution Channel (USD Million)
8.1. Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Distribution Channel, 2023-2033
8.2. Hospital Pharmacy
8.3. Drug Store and Retail Pharmacy
8.4. Online Pharmacy
9. Global Alzheimer’s Therapeutics Market, By Drug Name (USD Million)
9.1. Global Alzheimer’s Therapeutics Market Value Share and Forecast, By Drug Name, 2023-2033
9.2. Donepezil
9.3. Galantamine
9.4. Manufactured Combination of Memantine and Donepezil
9.5. Memantine
9.6. Rivastigmine
10. Global Alzheimer’s Therapeutics Market Forecast, 2019-2033 (USD Million)
10.1. Global Alzheimer’s Therapeutics Market Size and Market Share
11. Global Alzheimer’s Therapeutics Market, By Drug Class, 2019-2033 (USD Million)
11.1. Global Alzheimer’s Therapeutics Market Size and Market Share By Drug Class (2019-2026)
11.2. Global Alzheimer’s Therapeutics Market Size and Market Share By Drug Class (2027-2033)
12. Global Alzheimer’s Therapeutics Market, By Distribution Channel, 2019-2033 (USD Million)
12.1. Global Alzheimer’s Therapeutics Market Size and Market Share By Distribution Channel (2019-2026)
12.2. Global Alzheimer’s Therapeutics Market Size and Market Share By Distribution Channel (2027-2033)
13. Global Alzheimer’s Therapeutics Market, By Drug Name, 2019-2033 (USD Million)
13.1. Global Alzheimer’s Therapeutics Market Size and Market Share By Drug Name (2019-2026)
13.2. Global Alzheimer’s Therapeutics Market Size and Market Share By Drug Name (2027-2033)
14. Global Alzheimer’s Therapeutics Market, By Region, 2019-2033 (USD Million)
14.1. Global Alzheimer’s Therapeutics Market Size and Market Share By Region (2019-2026)
14.2. Global Alzheimer’s Therapeutics Market Size and Market Share By Region (2027-2033)
14.3. Asia-Pacific
14.3.1. Australia
14.3.2. China
14.3.3. India
14.3.4. Japan
14.3.5. South Korea
14.3.6. Rest of Asia-Pacific
14.4. Europe
14.4.1. France
14.4.2. Germany
14.4.3. Italy
14.4.4. Spain
14.4.5. United Kingdom
14.4.6. Rest of Europe
14.5. Middle East and Africa
14.5.1. Kingdom of Saudi Arabia
14.5.2. United Arab Emirates
14.5.3. Rest of Middle East & Africa
14.6. North America
14.6.1. Canada
14.6.2. Mexico
14.6.3. United States
14.7. Latin America
14.7.1. Argentina
14.7.2. Brazil
14.7.3. Rest of Latin America
15. Company Profile
15.1. AbbVie inc.
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary
15.1.4. Recent developments
15.2. Amneal Pharmaceuticals Inc.
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary
15.2.4. Recent developments
15.3. Aurobindo Pharma Ltd.
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary
15.3.4. Recent developments
15.4. Biogen, Merck & Co. Inc.
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary
15.4.4. Recent developments
15.5. Cipla Ltd.
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary
15.5.4. Recent developments
15.6. DAIICHI SANKYO COMPANY, LIMITED
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary
15.6.4. Recent developments
15.7. Dr. Reddy’s Laboratories Ltd.
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary
15.7.4. Recent developments
15.8. Eisai Co. Ltd.
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary
15.8.4. Recent developments
15.9. Eli Lilly and Company
15.9.1. Company details
15.9.2. Financial outlook
15.9.3. Product summary
15.9.4. Recent developments
15.10. H. Lundbeck A/S
15.10.1. Company details
15.10.2. Financial outlook
15.10.3. Product summary
15.10.4. Recent developments
15.11. Janssen Pharmaceuticals, Inc.
15.11.1. Company details
15.11.2. Financial outlook
15.11.3. Product summary
15.11.4. Recent developments
15.12. Lannett Inc.
15.12.1. Company details
15.12.2. Financial outlook
15.12.3. Product summary
15.12.4. Recent developments
15.13. Lupin Ltd.
15.13.1. Company details
15.13.2. Financial outlook
15.13.3. Product summary
15.13.4. Recent developments
15.14. Macleods Pharmaceuticals Ltd.
15.14.1. Company details
15.14.2. Financial outlook
15.14.3. Product summary
15.14.4. Recent developments
15.15. Novartis AG
15.15.1. Company details
15.15.2. Financial outlook
15.15.3. Product summary
15.15.4. Recent developments
15.16. Sun Pharmaceuticals Industries Ltd.
15.16.1. Company details
15.16.2. Financial outlook
15.16.3. Product summary
15.16.4. Recent developments
15.17. Teva Pharmaceuticals Industries Ltd.
15.17.1. Company details
15.17.2. Financial outlook
15.17.3. Product summary
15.17.4. Recent developments
15.18. Torrent Pharmaceuticals Ltd.
15.18.1. Company details
15.18.2. Financial outlook
15.18.3. Product summary
15.18.4. Recent developments
15.19. Unichem Laboratories Ltd.
15.19.1. Company details
15.19.2. Financial outlook
15.19.3. Product summary
15.19.4. Recent developments
15.20. Viatris Inc.
15.20.1. Company details
15.20.2. Financial outlook
15.20.3. Product summary
15.20.4. Recent developments
15.21. Zydus Lifesciences Ltd.
15.21.1. Company details
15.21.2. Financial outlook
15.21.3. Product summary
15.21.4. Recent developments
15.22. Others
16. List of Abbreviations
17. Reference Links
18. Conclusion
19. Research Scope